Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FDA Clears AbbVie's Rinvoq For Moderate To Severe Active Ulcerative Colitis

  • The FDA approved AbbVie Inc's (NYSE:ABBV) Rinvoq (upadacitinib) for adults patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blockers. 
  • This FDA approval is the first indication for Rinvoq in gastroenterology and is supported by efficacy and safety data from three Phase 3 clinical studies.
  • Across all clinical trials, significantly more patients treated with Rinvoq achieved clinical remission at weeks 8 and 52, the primary endpoint, compared to placebo. 
  • Read Next: JAK Inhibitors Come Under EMA Scrutiny On Safety Concerns: All You Need To Know.
  • In addition, the studies met all ranked secondary endpoints, including endoscopic improvement and histologic-endoscopic mucosal improvement (HEMI), as well as corticosteroid-free clinical remission in the maintenance study. 
  • Price Action: ABBV shares are up 0.01% at $156.06 during the premarket session on the last check Thursday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.